{
    "nctId": "NCT02429583",
    "officialTitle": "Effects of Persistent Innate Immune Activation on Vaccine Efficacy",
    "inclusionCriteria": "* Willing to receive three doses of an FDA-approved Hepatitis B vaccine\n* Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies)\n* Healthy volunteer without significant medical problems\n* Must have minimum age of 18 Years\n* Must have maximum age of 62 Years",
    "exclusionCriteria": "* Received any vaccine within a month prior to study vaccine\n* Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen\n* HIV positive\n* For HCV-negative, healthy volunteers: History of HCV infection or positive HCV antibody test\n* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study\n* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol\n* Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group)\n* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications\n* Any clinically significant acute or chronic medical condition requiring care by a primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation\n* Unable to continue participation for 156 weeks\n* History of previous Hepatitis B vaccination(s)\n* Male or female \\< 18 and \\> 62 years of age\n* Is pregnant or lactating\n* History of Hepatitis B infection\n* Clinical, laboratory, or biopsy evidence of cirrhosis"
}